Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Down – Here’s What Happened

Posted by Brian Himes on Jun 9th, 2026

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY – Get Free Report)’s stock price gapped down prior to trading on Tuesday . The stock had previously closed at $23.50, but opened at $22.69. Chugai Pharmaceutical shares last traded at $23.0950, with a volume of 19,079 shares changing hands.

Analysts Set New Price Targets

Several equities research analysts have commented on CHGCY shares. Zacks Research raised shares of Chugai Pharmaceutical to a “hold” rating in a report on Friday, May 29th. Smbc Nikko Sec. raised shares of Chugai Pharmaceutical to a “strong-buy” rating in a report on Wednesday, February 25th. Two equities research analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Chugai Pharmaceutical presently has a consensus rating of “Buy”.

Read Our Latest Research Report on Chugai Pharmaceutical

Chugai Pharmaceutical Stock Down 4.5%

The company has a market cap of $73.88 billion, a price-to-earnings ratio of 24.94 and a beta of 0.58. The company’s 50-day moving average is $25.94 and its 200 day moving average is $27.28.

Chugai Pharmaceutical (OTCMKTS:CHGCY – Get Free Report) last released its quarterly earnings results on Friday, April 24th. The company reported $0.22 EPS for the quarter. The company had revenue of $2.05 billion for the quarter. Chugai Pharmaceutical had a net margin of 34.98% and a return on equity of 22.90%. Analysts predict that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.98 EPS for the current fiscal year.

About Chugai Pharmaceutical

(Get Free Report)

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.